Know What's Happening in Healthcare
Know What's Happening in Healthcare
FDA approves KRESLADI, first CIRM‑backed gene‑editing therapy
The FDA cleared KRESLADI, a gene‑editing treatment from Rocket Pharmaceuticals for severe leukocyte adhesion deficiency‑I in children, eliminating the need for a bone‑marrow donor. It is the first product directly funded by California’s Institute for Regenerative Medicine to receive approval.
Also developing:
By the numbers: Syneron Bio raises $150M Series B
Health‑tech AI pilots are booming, yet MIT’s 2025 State of AI report finds 95% fail to generate value. High‑profile failures like Forward Health’s CarePods and Olive AI illustrate how operational complexity and unfocused expansion derail scaling. The article argues that success hinges on early governance alignment, scalable architecture, and addressing clinician workflow friction. Tailoring deployments for mid‑size hospitals further improves adoption prospects.
The module outlines a five‑dimensional framework for target selection, linking biological relevance, drugability, disease impact, competitive landscape, and development risk. It contrasts first‑in‑class and best‑in‑class strategies, highlighting how pioneering mechanisms can command premium market positions. The content identifies oncology as...
Ultima Genomics announced the UG 200 series, a second‑generation sequencing platform that includes a single‑wafer UG 200 and a dual‑wafer UG 200 Ultra. Both instruments are half the size of the UG 100, cost less (starting at $850,000), and deliver...
GH Research’s inhaled mebufotenin (GH001) demonstrated ultra‑rapid, profound antidepressant effects in a Phase 2b trial for treatment‑resistant depression, with 73% of patients in remission after six months versus ~11% for standard oral therapies. Early‑stage studies in postpartum depression and bipolar disorder...
Gilead Sciences agreed to acquire the remaining shares of Arcellx for an equity value of $7.8 billion, paying $115 per share—a 79.4% premium to the prior close. The deal secures full rights to Arcellx’s BCMA‑directed CAR‑T therapy anito‑cel, which is in...
Asda Opticians is committing £2.5 million to upgrade its optical estate, refit 18 stores and modernise diagnostic equipment. The investment also funds a new suite of technical, leadership and personal‑development training, plus a third Level 6 Dispensing Optician apprenticeship cohort beginning September 2026....
Healthcare scheduling is evolving from a back‑office task into a core operational layer within Salesforce. As providers consolidate patient data, billing, and analytics on the CRM, real‑time coordination of staff, rooms, equipment, and services becomes essential. The article outlines common...
Gossamer Bio announced that its Phase 3 trial of seralutinib for pulmonary arterial hypertension missed its primary endpoint. Patients on seralutinib walked 13 meters farther than placebo over six minutes, but the difference lacked statistical significance. The trial also reported cough...
A January 2026 KFF poll shows only 47% of Americans trust the CDC, down from 63% in September 2023. Trust has eroded across the political spectrum, with Democrats at 55%, Republicans at 43%, and independents at 46%. The decline began...
A Lancet Digital Health study evaluated 20 large language models with over three million medical prompts, revealing a high susceptibility to misinformation. Neutral prompts led to a 32% acceptance rate of false information, which rose to 46% when embedded in...
At the BIO Investor Growth (BIG) Summit, IBD Ventures’ associate director Nicole Schwerbrock discussed how venture philanthropy and patient advocacy are reshaping investment in inflammatory bowel disease (IBD) research. She explained that patient‑driven funding models complement traditional venture capital by...
The U.S. Department of Health and Human Services (HHS) awarded nearly $900 million in FY 2024 through its Public Health Emergency Preparedness (PHEP) and Hospital Preparedness Program (HPP) to state and local jurisdictions. GAO found that the two HHS agencies managing these...
Bandages have been a central component of wound healing for centuries. In the digital health era, the wound healing process will transform the role of bandages from a passive to an active one. We dive into the current and future innovations of...
Goal-Driven Flexible Bayesian Design presentation updated w/comparison of performance of frequentist group sequential designs: https://t.co/QCZ6DQrm07 . Frequentist approach takes far too long to make a decision by controlling something that is NOT an error prob. #Statistics #rct https://t.co/X2knbmzTuX
The U.S. Centers for Medicare & Medicaid Services (CMS) has renewed the Accreditation Commission for Health Care’s (ACH C) deemed status as an accreditor for both hospice providers and critical‑access hospitals. The six‑year renewal, effective through 2031, confirms that ACHC’s standards...
My @CNBC segment on how President Trump's drug pricing deals will achieve many of the initial aims set out by tariff proposals, with respect to reshoring drug manufacturing, and how the biggest consumer impact in terms of lower drug costs...
Evaluating a doctor-in-the-loop AI-agent for multiple myeloma chart reviews [Nov 3, 2025] Karla Mariana Castro Bórquez et al. @HealthTree #ASH25 abs25-15262 PID 4424 https://t.co/MvBeHqOxCg #mmsm #AI #EMR #RWD https://t.co/onY817NfVr
Texas has filed its Required Initial Disclosures in the antitrust lawsuit against Epic Systems, revealing a 12‑category disclosure regime that exceeds the federal FRCP 26 standard. The State’s witness list includes senior Epic executives, technical leaders, recruiting staff, several Epic‑using health...
Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants [Nov 3, 2025] Rajanna et al. @DrOlaLandgren #ASH25 abs25-11635 PID 4008 https://t.co/gOprMCjfgh #mmsm #AI #oncopath https://t.co/pjikEsgfHC
Race agnostic models maintain accuracy in predicting M-protein levels in multiple myeloma [Nov 3, 2025] @rahul2u et al. #ASH25 abs25-11347 PID 2810 https://t.co/A27ozBoW8h #mmsm #AI #CancerDisparities https://t.co/ubJ6NGMFUE
The United States continues to spend more on health care than any other nation while delivering poorer health outcomes, a gap the article attributes to a profit‑driven insurance model. The author argues that incremental reforms have failed and proposes a...
Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States [Nov 3, 2025] @MalekEhsanMD et al. #ASH25 abs25-11278 PID 2809 https://t.co/mAC8l7xnaG #mmsm #cancerdisparities #hpeonc https://t.co/veJxBV5S0N
Patient perspectives & preferences for step-up dosing and treatment w/ teclistamab & talquetamab: Insights from a patient survey [Nov 3, 2025] @JayHydren et al. @RahulBanerjeeMD abs25-8335 PID 6354 https://t.co/pRlflaSb2I #mmsm #Tcellrx @HealthTree https://t.co/3I9nwsxZMx
A February 2026 KLAS Research analysis of 19 health‑system IT outsourcing decisions found pre‑existing vendor relationships to be the top driver of managed‑IT services selection, eclipsing cost, expertise and credibility. The study identified five firms—CereCore, HCTec, Nordic, Impact Advisors and CTG—as...
The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 https://t.co/X2pdaIDYth #mmsm
Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey [Dec 7, 2024] @ManniMD1 et al. - @HealthTree https://t.co/jATJRKEfB2 #ASH24 Abst 2281 #mmsm HT @Taxkourel
New research indicates that routine AI assistance can erode physicians' clinical instincts, a phenomenon termed de‑skilling. A 2025 Lancet study found endoscopists' adenoma detection rates dropped from 29% to 22% after regular AI use, suggesting skill decay in non‑AI procedures....
Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in Relapsed Refractory Multiple Myeloma [Dec 8, 2024] Martinez et al. #ASH24 Abst 706 https://t.co/l7SHPBwbna #mmsm HT @Taxkourel
The effect of care team-patient relationship on decision-making in relapsed/refractory multiple myeloma - @MyelomaTeacher et al. @HealthTree #ASCO24 Abstract e19530 https://t.co/Ss5LZHH0Oj #mmsm
Researchers identified oligodendrocyte myelin glycoprotein (OMG) in blood as a marker inversely associated with cortical amyloid‑β deposition and neurodegeneration. Large‑scale plasma proteomics across more than a dozen cohorts showed lower OMG levels in individuals with Alzheimer’s disease, other dementias, and...
A survey on the patient perspective on cure in multiple myeloma [Oct 9, 2022] @ManniMD1 et al. @HealthtreeMM @TheLancetHaem https://t.co/1XhKT7AWGi #mmsm
.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO https://t.co/WOwLb9Eozv @myelomacrowd #mmsm https://t.co/dZzhU3N32Q
Jay Bregman, CEO of Andel, says the FDA’s pending crackdown on non‑FDA‑approved GLP‑1 compounds is long overdue and will target the burgeoning market of compounded semaglutide. He estimates roughly 1.5 million patients currently rely on these unapproved products, a figure he...
. @HealthtreeMM Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - @NSweeneyPhd @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath https://t.co/m1UGDimLWm
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/FjBnt6yIox
BioNTech has filed a Delaware patent‑infringement lawsuit against Moderna, accusing the latter’s next‑generation COVID vaccine mNEXSPIKE of using BioNTech’s streamlined mRNA design. The disputed shot is projected to generate about 55 % of Moderna’s COVID revenue this season, making the case...
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/QdWETmSoiR
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/paGRlHV1Dv
Northwell Health announced the temporary closure of a 30‑bed unit at its Orzac Center for Rehabilitation in Valley Stream, resulting in the layoff of more than 30 union workers, including licensed practical nurses, certified nursing assistants and physical therapists. The...
Jan Herzhoff, president of global health businesses at Elsevier, emphasized the importance of critical thinking over sole reliance on AI to prevent de-skilling in healthcare at the India AI Impact Summit 2026. https://t.co/hexOguFdCt #AI #Elsevier #health #India
Partner Therapeutics presented post‑hoc data from its Phase II eNRGy study of zenocutuzumab (Bizengri) in 27 patients with advanced NRG1‑positive non‑small cell lung cancer who received at least three doses beyond radiographic progression. Eight patients stayed on therapy for six months...
Novo Nordisk’s next‑generation obesity drug CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide in the 84‑week REDEFINE 4 study, achieving 20.2% weight loss versus 23.6% for tirzepatide. The open‑label trial showed the two treatments were not statistically equivalent. Following the announcement,...
Pharmaceutical logistics faces $38 billion annual waste due to fragmented temperature‑controlled networks and customs delays. Frontier Scientific Solutions, based in Wilmington and Shannon, has built a purpose‑built, cGMP‑grade infrastructure that integrates storage, monitoring and direct airside access. By consolidating routes, the...
PRECISIS GmbH’s EASEE® epicranial neurostimulation system offers a minimally invasive alternative for drug‑resistant focal epilepsy. The implant, positioned under the scalp atop the skull, delivers targeted electrical pulses without opening the skull, achieving a median 68% seizure reduction over two...
Johnson & Johnson released long‑term QUASAR extension data for Tremfya (guselkumab) in ulcerative colitis, showing sustained efficacy through week 140. Clinical remission was achieved by 80.8% of patients, with 78.6% attaining histo‑endoscopic improvement and 53.6% reaching endoscopic remission. Approximately 89% of...
The 2025 earnings season highlighted a clear hierarchy among healthcare giants, with Eli Lilly and AstraZeneca leading pharma revenue growth and Medtronic and Edwards Lifesciences topping medtech sales. The podcast hosted by Robert Barrie and Ross Law breaks down the financial results, noting...
Researchers have demonstrated dissolving microneedle (DMN) arrays fabricated using resin‑based 3D‑printed master molds, enabling drug delivery through the inner cheek. The workflow pairs rapid SLA/DLP printing with polymer micromolding, allowing design changes from CAD to mold within hours. Mechanical, dissolution...
Health Secretary Robert F. Kennedy Jr. has pledged to purge industry influence from the FDA, yet the Trump administration’s injection of political priorities has reshaped the agency’s operating environment. Under the current administration, discussions that once were deemed off‑limits between...
Handheld ultrasound systems are reshaping point‑of‑care imaging by delivering portable, real‑time diagnostic capability directly at the bedside. Their lightweight design allows clinicians to move quickly between patients, cutting imaging wait times and supporting rapid decision‑making in emergencies. The technology also...
Scotland’s cancer diagnosis pathway is lagging, with only 69.9% of urgent referrals meeting the 62‑day treatment target, well short of the 95% benchmark. The National Framework for Effective Cancer Management (2025) outlines ten steps to streamline care, but implementation remains...
